Intrathecal Pumps Market

Intrathecal Pumps Market: Overview

The Intrathecal Pumps Market is valued at USD 450.3 Bn in 2026 and is projected to reach USD 642.1 Bn,  growing at a CAGR of 5% by 2033. An intrathecal pump is a surgically implanted technology that delivers powerful medications straight into or near the spinal cord. These pumps are primarily used in chronic pain and spasticity therapy to deliver strong medicines in the intrathecal region, allowing pharmaceuticals to be administered in extremely low doses. The increase in chronic diseases such as cancer, back pain, and chronic pancreatitis is expected to boost the industry's growth. According to the National Cancer Institute, there were around 16.9 million cancer-affected patients in the United States in January 2019. As a result, rising cancer incidences are likely to fuel significant development potential. Intrathecal pump technological advances are likely to boost market growth. Improvements in pump delivery modalities, catheter design, and safety features, among other things, are expected to boost its adoption rate. A growing number of product releases by well-known companies is expected to enhance industry growth. Amneal Pharmaceuticals announced the launch of LYVISPAH  in June 2022 to treat spasticity caused by multiple sclerosis and other spinal cord disorders. Intrathecal pump technological advancements may hasten market growth. Its adoption rate is expected to rise due to enhanced pump delivery modes, catheter design, and safety features. Baclofen risks the business since it can be lethal, resulting in convulsions, unconsciousness, rhabdomyolysis, and death. Forecasts show that the market will expand as more well-known companies produce new items.

Furthermore, intrathecal pump makers have been reported to advance devices with longer battery life, which may assist reduce the number of future surgical procedures required to replace expiring pumps. The rising incidence of pain disorders is expected to propel the sector forward. Cancer pain is becoming more common as oncologic patients' survival rates improve. Pain is one of the most common symptoms in 67% of people with metastatic disease. Most persistent cancer pain can be controlled with pharmacologic treatments such as analgesia. However, intrathecal drug delivery provides an alternate route of administration for analgesics, lowering adverse effects and improving bioavailability, boosting market expansion. ITDD system difficulties, such as pharmaceutical, surgical, mechanical, and patient-specific issues, are expected to impede market growth.

Intrathecal Pumps Market: COVID-19 Impact

The pandemic of COVID-19 had just a minimal impact on industry growth. Pandemic-induced social and healthcare disruptions may represent a significant risk to patients who use an intrathecal pump and may miss replacement or refill visits, resulting in severe withdrawal syndrome and driving business expansion. In the case of baclofen, this could be fatal, with complications such as seizures, rhabdomyolysis, coma, and death, posing a challenge to the business. The COVID-19 epidemic posed significant hurdles to the healthcare sector. Because most chronic pain services were regarded as non-urgent, all Intrathecal Pumps (ITP) refill procedures were insufficient or halted during the pandemic to prevent virus transmission.

Cancer and Other Chronic Diseases to Propels Market For Intrathecal Pumps

Chronic pain is a leading cause of disability and imposes a significant financial and social burden. The National Cancer Institute reports that the annual growth rate of new cancer cases is 442.4 per 100,000 people. According to the Centers for Disease Control and Prevention, 67 million persons in the United States will have doctor-diagnosed arthritis by 2025. Intrathecal pumps are preferable to oral prescriptions because they work directly on the cerebrospinal fluid (CSF), allowing medications to be digested more quickly and readily. Cancer, Rheumatoid Arthritis, fibromyalgia, and nerve damage, among other chronic illnesses, are harmful to a person's health because they reduce immunity and cause chronic discomfort. Adults and the elderly are the most commonly affected by the illnesses above. According to CDC data from October 2019, one in every ten adults in the United States has at least one chronic condition. Furthermore, four out of every ten people in the country have two chronic conditions simultaneously.

Many chronic diseases are becoming more common in adolescent and adult populations. Furthermore, common illnesses such as rheumatoid arthritis and certain musculoskeletal problems resulting from sports and industrial injuries are major causes of persistent pain. This discomfort increases a person's dependency on others for daily duties, making pain management a key responsibility for sustaining routine normalcy. Intrathecal pumps provide relief for extended periods while also enhancing patients' health. As a result, the rising frequency of cancer and other chronic diseases is a growing demand for intrathecal pumps, propelling the market forward.

Technology Advancement is Driving Market Growth

The market is expanding due to technical developments such as a pump's capacity to distribute medications directly to the site of need, decreased systemic exposure, increased potency, and the quantity necessary to achieve the desired pharmacologic effect. Intrathecal pumps are used for accurate medicine dosage transfers within the human body, particularly the spinal cord. Intrathecal pumps are often used to treat chronic pain patients with few side effects. Because intrathecal pumps work directly in the CSF, they allow faster and more efficient drug absorption than oral therapies. 

Inequality Issues, Combined With Costly Cell Therapy Therapies to Hamper Market Growth

ITDD System difficulties such as pharmacological complications, surgical complications, mechanical system issues, and patient-specific complications are expected to reduce the market share. Such difficulties may arise during the pump refill due to a reprogramming or prescription error, resulting in systemic toxicity or death.

Intrathecal Pumps Market: Segment Overview

Bupivacaine has Largest Share due to its Excellent Ability of Supplemental Medication

The bupivacaine segment is predicted to have the largest market share. Bupivacaine is recognized as an excellent supplemental medication in intrathecal therapy. Numerous studies have demonstrated that when combined with intrathecal opioids, bupivacaine dramatically increases its market share. Because of bupivacaine, some patients may require fewer oral opioids, limiting dosage increases in intrathecal opioids. As a result, the benefits of bupivacaine are expected to ensure the segment's growth.

Furthermore, the baclofen type category is expected to grow fast over the forecast period. Intrathecal baclofen treatment effectively lowers spasticity and pain in many central pain diseases such as SCI, post-stroke, and musculoskeletal pain. As a result, growing pain and spasticity levels are expected to contribute to the segment's growth.

With an Increased in Cancer Patients, Pain Category Dominated Market

The pain sector dominated the market and is likely to continue throughout the forecast period. The rising number of acute and chronic disorders such as pain-causing ailments such as failed back surgery syndrome and chronic pain cancer is one of the main factors driving sector growth. The capacity of devices to manage chronic aches with modest doses has raised product demand in the senior population, who are more prone to chronic pain.

North America to Dominate Market due to Increasing R&D Expenditure

It is anticipated that the North American market will account for the largest revenue share. Well-developed primary, secondary, and tertiary care hospitals aided market growth in North America. Furthermore, a solid reimbursement network and attractive government funding are expected to drive market expansion. The rising collective efforts of key market companies to improve their product portfolio and ensure high-quality standards are expected to drive intrathecal pump demand across this region. The increasing R&D expenditure, high prevalence of pain-related disorders, and the growing number of pain care centers in the US and Canada contributed significantly to the region's growth. The prevalence of cancer in the United States is rapidly increasing, resulting in a growing demand for effective and improved intrathecal pumps. Cancer and persistent postoperative pain, as well as neck discomfort, which enables the administration of pain medications, are projected to fuel market growth. According to  Centers for Disease Control and Prevention  2020, chronic pain affects 50 million people in the United States (US).

Aside from patient safety, other programs have been launched in the United States to increase healthcare quality at an economical cost. Another factor driving market expansion is that North America spends more on healthcare than other areas. The North American Spine Society (NASS) issued comprehensive guidelines on spinal intrathecal delivery systems to treat persistent pains in January 2021. According to the North American Spine Society (NASS), the spinal intrathecal delivery system procedure may affect a small number of people with chronic pain and spinal damage. This procedure may be useful in people who have exhausted all other treatment choices for their symptoms. These individuals should be evaluated psychologically to rule out drug and alcohol addictions and other psychiatric illnesses. Compared to conventional procedures, this approach provides patients with fewer adverse and therapeutic effects. The expansion of the North American market is linked to the government's favorable health insurance policies and increased awareness of intrathecal pumps among patients suffering from chronic pain in North America.

In September 2021, Novartis Gene Therapies launched a new pivotal confirmatory study to investigate the usage of AVXS-101 intrathecal (IT) formulation in older patients with Spinal Muscular Atrophy (SMA) to forward the AVXS-101 regulatory submission. Moreover, in October 2019, The FDA has approved Flowonix Medical's Prometra II 40 ml programmable pump for use with intrathecal baclofen. This product launch enabled the company to give cancer patients a Prometra system for serving 40 ml pumps.

Some Intrathecal Pumps Market players include 

• Medtronic plc
• Flowonix Medical, Inc.
• Codman & Shurtleff, Inc. (part of Integra LifeSciences)
• PainCare Labs, Inc.
• Stryker Corporation
• Abbott Laboratories
• Braun Melsungen AG
• Halyard Health (Part of Owens & Minor)
• Smiths Medical (ICU Medical, Inc.)
• Boston Scientific Corporation
• Ipsen Pharma
• Teva Pharmaceutical Industries Ltd.
• Mallinckrodt Pharmaceuticals
• Pfizer Inc.
• AbbVie Inc.

By Product Type

• Implantable Pumps
• External (Percutaneous) Pumps
• Refillable / Non refillable Pumps

By Technology

• Electronic / Programmable Pumps
• Mechanical Pumps

By Application

• Chronic Pain Management
• Spasticity
• Other Neurological Disorders

By End User

• Hospitals & Surgery Centers
• Pain Clinics
• Home Healthcare

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa